Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.22.2.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

(14) Stock-Based Compensation

The Company has adopted the 2019 Plan that allows for the grant of stock options, stock appreciation rights and stock awards for an initial total of 85,714 shares of common stock. On December 1st of each year, pursuant to the “Evergreen” provision of the 2019 Plan, the number of shares available under the plan shall be increased by an amount equal to 5% of the outstanding common stock on December 1st of that year or such lower amount as determined by the Board of Directors. In December 2021, the number of shares available for issuance under the 2019 Plan was increased by 120,605. The total number of shares authorized for issuance under the 2019 Plan as of September 30, 2022 is 263,167. As of September 30, 2022, 115,442 shares are available for future grants under the 2019 Plan.

Stock Options:

Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. There were no options granted during the nine months ended September 30, 2022. The weighted average grant-date fair value of options awarded to employees during the nine months ended September 30, 2021 was $25.39.

Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:

 

 

 

 

September 30,

 

 

 

2021

 

Expected option life

 

5.6 years

 

Expected volatility

 

75.16%

 

Risk-free interest rate

 

0.84%

 

Expected dividend yield

 

 

 

 

The following table summarizes Baudax Bio stock option activity during the nine months ended September 30, 2022:

 

 

 

Number of
shares

 

 

Weighted
average
exercise
price

 

 

Weighted
average
remaining
contractual life

Balance, December 31, 2021

 

 

125,418

 

 

$

76.05

 

 

8.6 years

Expired/forfeited/cancelled

 

 

(41,980

)

 

$

54.41

 

 

 

Balance, September 30, 2022

 

 

83,438

 

 

$

86.94

 

 

7.7 years

Vested

 

 

58,987

 

 

$

87.18

 

 

7.4 years

Vested and expected to vest

 

 

83,438

 

 

$

86.94

 

 

7.7 years

 

Included in the table above are 3,229 stock options outstanding as of September 30, 2022 that were granted outside of the plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

Restricted Stock Units (RSUs):

The following table summarizes Baudax Bio RSUs activity during the nine months ended September 30, 2022:

 

 

 

Number of
shares

 

 

Weighted
average
grant date
fair value

 

Balance, December 31, 2021

 

 

41,069

 

 

$

63.79

 

Granted

 

 

501,209

 

 

 

0.76

 

Vested and settled

 

 

(11,909

)

 

 

47.72

 

Expired/forfeited/cancelled

 

 

(7,155

)

 

 

57.79

 

Balance, September 30, 2022

 

 

523,214

 

 

$

3.86

 

Expected to vest

 

 

508,088

 

 

 

 

 

 

In June 2022, the Company granted 501,209 time-based RSUs, which may be settled in cash, stock, or a combination of cash and stock, solely at the election of the Company. These awards are classified as Other long-term liabilities on the Consolidated Balance Sheet due to insufficient shares available for grant in the 2019 Plan.

Included in the table above are 627 time-based RSUs outstanding as of September 30, 2022 that were granted outside of the plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).

Stock-Based Compensation Expense:

Stock-based compensation expense for the nine months ended September 30, 2022 and 2021 was $1,172 and $4,132, respectively, which for the current year also includes expense for the liability classified awards.

As of September 30, 2022, there was $1,701 of unrecognized compensation expense related to unvested options and time-based RSUs that are expected to vest and will be expensed over a weighted average period of 1.5 years. As of September 30, 2022, there was $450 of unrecognized compensation expense related to unvested performance-based RSUs.

The aggregate intrinsic value represents the total amount by which the fair value of the common stock subject to options exceeds the exercise price of the related options. As of September 30, 2022, there was no aggregate intrinsic value of the vested and unvested options.